Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259699 | 0.87 | CNR1 (0.59) | CNR1GAAABL1BCRL3MBTL1 | |
| SCHEMBL26970150 | 0.77 | ALDH1A1 (0.70) | GAAL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL1155886 | 0.76 | ATM (0.50) | L3MBTL1POLBALDH1A1LMNAATM | |
| SCHEMBL31436933 | 0.76 | ATM (0.50) | L3MBTL1POLBALDH1A1LMNAATM | |
| SCHEMBL17843453 | 0.76 | CNR1 (0.52) | CNR1GAAABL1BCRL3MBTL1 | |
| SCHEMBL4267203 | 0.75 | CNR1 (1.00) | CNR1L3MBTL1 | |
| SCHEMBL2637275 | 0.74 | CNR1 (0.47) | CNR1GAAABL1BCRL3MBTL1 | |
| SCHEMBL15916140 | 0.73 | EPHX2 (0.55) | L3MBTL1ALDH1A1ATMHTTSMN1; SMN2 | |
| SCHEMBL11292063 | 0.73 | ACP1 (0.49) | CNR1GAAABL1BCRL3MBTL1 | |
| SCHEMBL30253146 | 0.73 | NOTUM (0.49) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102036961-A | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | CNR1 105/4885GAA 982/4885ABL1 1423/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | CNR1 105/4885GAA 982/4885ABL1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.